leisure time -WSS

leisure time

author：knowledge 2025-09-28 20:44:27 - browse：36488

Amid the stunning rebuke Amgen suffered at the hands of the U.S. Food and Drug Administration this week lurk numerous questions. And one of them may be whether the company was fully forthcoming about a pricey lung cancer drug that is supposed to generate key revenue growth.

At issue is a trial that Amgen is relying upon to win final approval for Lumakras, which the FDA approved on a conditional basis in 2021. This process, known as accelerated approval, required the company to run a confirmatory study. But ahead of an advisory panel meeting on Thursday, the agency released documents showing its staff found “potential systemic bias” in the trial.

The disclosure throws into question the future of this drug, which has offered hope to patients for whom an effective treatment previously seemed out of reach. Some Wall Street analysts are now betting the FDA will ask Amgen to run yet another trial or maybe withdraw the drug altogether. Either way, the prognosticators are reworking their calculus for Amgen stock.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： At JPM 2024, hospital systems pitch financial strength to investors

WSS

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Former medical device CEO who sold dummy, plastic parts convicted of fraud

Allen Institute goes after foundational questions, CEO Costa says

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

hotspot

leisure time

leisure time

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Study suggests new cause of Down syndrome: cells linked to aging

In age of alternative facts, a scholarly course on calling out crap

American taxpayers paid $1.8 trillion in health care costs in 2022

How one medical school became remarkably diverse

Study suggests new cause of Down syndrome: cells linked to aging

Cancer drug shortages should be causing more outrage

Novo Nordisk obesity pill bests Wegovy in early trial

In age of alternative facts, a scholarly course on calling out crap

In his State of the Union, Biden takes clear aim at 'Big Pharma'

knowledge

Headspace, Meta partner to launch VR meditation app for Quest

In his State of the Union, Biden takes clear aim at 'Big Pharma'

Study suggests new cause of Down syndrome: cells linked to aging

Just how do doctors, lawmakers, and the public define abortion?

Hospital chaplains balance Covid safety with patients’ spiritual needs

CDC marks new Covid

knowledge

Wikipedia

hotspot

focus